(Q50926799)

25 March 2018

review article

1 reference

title

Building better magic bullets--improving unconjugated monoclonal antibody therapy for cancer. (English)

1 reference

25 March 2018

1 reference

1 reference

Louis M Weiner

1

1 reference

25 March 2018

language of work or name

English

0 references

publication date

1 September 2007

1 reference

25 March 2018

published in

Nature Reviews Cancer

1 reference

25 March 2018

volume

7

1 reference

25 March 2018

issue

9

1 reference

25 March 2018

page(s)

701-706

1 reference

25 March 2018

https://scigraph.springernature.com/pub.10.1038/nrc2209

exact match

0 references

cites work

Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu

1 reference

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia

31 March 2020

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

31 March 2020

1 reference

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

31 March 2020

1 reference

Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody

31 March 2020

1 reference

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

31 March 2020

1 reference

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

31 March 2020

1 reference

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

31 March 2020

1 reference

Panitumumab: a new anti-EGFR antibody for the treatment of advanced colorectal cancer

31 March 2020

1 reference

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

31 March 2020

1 reference

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

31 March 2020

1 reference

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

31 March 2020

1 reference

Mouse/human chimeric monoclonal antibody in man: kinetics and immune response

31 March 2020

1 reference

Production of functional chimaeric mouse/human antibody

31 March 2020

1 reference

Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains

31 March 2020

1 reference

Reshaping human antibodies for therapy

31 March 2020

1 reference

Phage antibodies: filamentous phage displaying antibody variable domains

31 March 2020

1 reference

Fully human therapeutic monoclonal antibodies

31 March 2020

1 reference

Complement function in mAb-mediated cancer immunotherapy

31 March 2020

1 reference

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

31 March 2020

1 reference

Engineered antibody Fc variants with enhanced effector function

31 March 2020

1 reference

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

31 March 2020

1 reference

The EGF receptor family as targets for cancer therapy

31 March 2020

1 reference

The ErbB signaling network: receptor heterodimerization in development and cancer

31 March 2020

1 reference

Angiogenesis as a therapeutic target

31 March 2020

1 reference

The ErbB receptors and their role in cancer progression.

31 March 2020

1 reference

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

31 March 2020

1 reference

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

31 March 2020

1 reference

Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma

31 March 2020

1 reference

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

31 March 2020

1 reference

Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells

31 March 2020

1 reference

Fcgamma receptors: old friends and new family members

31 March 2020

1 reference

Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies.

31 March 2020

1 reference

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

31 March 2020

1 reference

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

31 March 2020

1 reference

Immune evasion of tumor cells using membrane-bound complement regulatory proteins

31 March 2020

1 reference

Monoclonal antibodies as therapeutics in oncology

31 March 2020

1 reference

Monoclonal antibody therapy of cancer

31 March 2020

1 reference

Synthetic lethal screen identification of chemosensitizer loci in cancer cells

31 March 2020

1 reference

Comparing antibody and small-molecule therapies for cancer

31 March 2020

1 reference

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

31 March 2020

1 reference

Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity

31 March 2020

1 reference

Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format

31 March 2020

1 reference

Immune complex-mediated antigen presentation induces tumor immunity

31 March 2020

1 reference

Checkpoint blockade in cancer immunotherapy

31 March 2020

1 reference

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma

31 March 2020

1 reference

TeGenero fiasco prompts regulatory rethink

31 March 2020

1 reference

Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro

31 March 2020

1 reference

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

31 March 2020

1 reference

Bispecific antibodies in cancer therapy

31 March 2020

1 reference

Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu

31 March 2020

1 reference

A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity.

31 March 2020

1 reference

Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects

31 March 2020

1 reference

Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer

31 March 2020

1 reference

Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli

31 March 2020

1 reference

Health economic evaluations: the special case of end-stage renal disease treatment

31 March 2020

1 reference

A functional genomic screen identifies a role for TAO1 kinase in spindle-checkpoint signalling.

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRC2209

1 reference

25 March 2018

PubMed ID

17721434

1 reference

25 March 2018